To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.